

# Sandrine Andrieu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2942133/publications.pdf>

Version: 2024-02-01

257  
papers

18,854  
citations

22132

59  
h-index

14736

127  
g-index

270  
all docs

270  
docs citations

270  
times ranked

21722  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of a Cutoff for the Chair Stand Test as a Screening for Mobility Impairment in the Context of the Integrated Care for Older People Program. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2023, 78, 104-110.	1.7	4
2	Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials. <i>Alzheimer's and Dementia</i> , 2022, 18, 676-687.	0.4	8
3	Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 2140-2150.	0.4	17
4	Plasma MCP-1 and changes on cognitive function in community-dwelling older adults. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 5.	3.0	10
5	Sulcal morphology as cognitive decline predictor in older adults with memory complaints. <i>Neurobiology of Aging</i> , 2022, 113, 84-94.	1.5	1
6	Blood pressure, antihypertensive drugs, and incident frailty: The Multidomain Alzheimer Preventive Trial (MAPT). <i>Maturitas</i> , 2022, 162, 8-14.	1.0	7
7	Factors Predicting Engagement of Older Adults With a Coach-Supported eHealth Intervention Promoting Lifestyle Change and Associations Between Engagement and Changes in Cardiovascular and Dementia Risk: Secondary Analysis of an 18-Month Multinational Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e32006.	2.1	22
8	Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults. <i>GeroScience</i> , 2022, 44, 1489-1503.	2.1	3
9	Implementation of the WHO integrated care for older people (ICOPE) programme in clinical practice: a prospective study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e394-e404.	2.0	37
10	Nutrition state of science and dementia prevention: recommendations of the Nutrition for Dementia Prevention Working Group. <i>The Lancet Healthy Longevity</i> , 2022, 3, e501-e512.	2.0	26
11	Frequency of conditions associated with declines in intrinsic capacity according to a screening tool in the context of Integrated care for older people. <i>Journal of Frailty &amp; Aging</i> , 2021, 10, 1-8.	0.8	23
12	Kidney Function and Cognitive Decline in Older Adults: Examining the Role of Neurodegeneration. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 651-659.	1.3	12
13	What day is today? Cognitive capacity and the risk of incident dementia in the context of integrated care for older people (ICOPE Step 1). <i>Aging Clinical and Experimental Research</i> , 2021, 33, 3135-3139.	1.4	4
14	Visit-to-Visit Blood Pressure Variability and Incident Frailty in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1369-1375.	1.7	17
15	Development and Validation of a Model to Identify Alzheimer's Disease and Related Syndromes in Administrative Data. <i>Current Alzheimer Research</i> , 2021, 18, 142-156.	0.7	6
16	Prevention of dementia using mobile phone applications (PRODEMOS): protocol for an international randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e049762.	0.8	18
17	Screening for intrinsic capacity impairments as markers of increased risk of frailty and disability in the context of integrated care for older people: Secondary analysis of MAPT. <i>Maturitas</i> , 2021, 150, 1-6.	1.0	30
18	Disparities in the participation and adherence of older adults in lifestyle-based multidomain dementia prevention and the motivational role of perceived disease risk and intervention benefits: an observational ancillary study to a randomised controlled trial. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 157.	3.0	18

#	ARTICLE	IF	CITATIONS
19	Impact of pharmacist-led interventions on patient care in ambulatory care settings: A systematic review. <i>International Journal of Clinical Practice</i> , 2021, 75, e14864.	0.8	11
20	Cross-Sectional and Longitudinal Associations Between Plasma Neurodegenerative Biomarkers and Physical Performance Among Community-Dwelling Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1874-1881.	1.7	11
21	The INSPIRE research initiative: a program for GeroScience and healthy aging research going from animal models to humans and the healthcare system. <i>Journal of Frailty &amp; Aging</i> , 2021, 10, 1-8.	0.8	30
22	Framework Implementation of the INSPIRE ICOPE-CARE program in collaboration with the World Health Organization (WHO) in the Occitania region. <i>Journal of Frailty &amp; Aging</i> , 2021, 10, 1-7.	0.8	43
23	The INSPIRE Bio-resource Research Platform for Healthy Aging and Geroscience: Focus on the Human Translational Research Cohort (The INSPIRE-T Cohort). <i>Journal of Frailty &amp; Aging</i> , 2021, 10, 1-11.	0.8	17
24	Towards a large-scale assessment of the relationship between biological and chronological aging: The INSPIRE Mouse Cohort. <i>Journal of Frailty &amp; Aging</i> , 2021, 10, 1-11.	0.8	9
25	Cognitive function and amyloid marker in frail older adults: The COGFRIL Cohort Study. <i>Journal of Frailty &amp; Aging</i> , 2021, 10, 1-8.	0.8	3
26	Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study. <i>Journal of prevention of Alzheimer's disease</i> , 2021, 8, 1-11.	1.5	3
27	When is more better? Modeling the effect of dose on the efficacy of the MAPT multidomain intervention as a function of individual characteristics. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
28	Design and Development of a Mobile Health (mHealth) Platform for Dementia Prevention in the Prevention of Dementia by Mobile Phone Applications (PRODEMOS) Project. <i>Frontiers in Neurology</i> , 2021, 12, 733878.	1.1	5
29	REVISITING THE HALLMARKS OF AGING TO IDENTIFY MARKERS OF BIOLOGICAL AGE. <i>Journal of prevention of Alzheimer's disease</i> , 2020, 7, 1-9.	1.5	56
30	The association between apathy and frailty in older adults: a new investigation using data from the Mapt study. <i>Aging and Mental Health</i> , 2020, 24, 1985-1989.	1.5	8
31	Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1201-1209.	0.9	258
32	The impact of a multi-domain intervention on cerebral glucose metabolism: analysis from the randomized ancillary FDG PET MAPT trial. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 134.	3.0	7
33	Dementia risk scores as surrogate outcomes for lifestyle-based multidomain prevention trials: rationale, preliminary evidence and challenges. <i>Alzheimer's and Dementia</i> , 2020, 16, 1674-1685.	0.4	18
34	Screening for and Managing the Person with Frailty in Primary Care: ICFSR Consensus Guidelines. <i>Journal of Nutrition, Health and Aging</i> , 2020, 24, 920-927.	1.5	56
35	Meal-related difficulties and weight loss in older people: Longitudinal data from MAPT study. <i>Clinical Nutrition</i> , 2020, 39, 3483-3488.	2.3	3
36	Pooling individual participant data from randomized controlled trials: Exploring potential loss of information. <i>PLoS ONE</i> , 2020, 15, e0232970.	1.1	2

#	ARTICLE	IF	CITATIONS
37	Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial. <i>BMC Geriatrics</i> , 2020, 20, 99.	1.1	28
38	Worldwide FINGERS Network: A global approach to risk reduction and prevention of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1078-1094.	0.4	257
39	Systematic Dementia Screening by Multidisciplinary Team Meetings in Nursing Homes for Reducing Emergency Department Transfers. <i>JAMA Network Open</i> , 2020, 3, e200049.	2.8	11
40	Prospective Associations Between Diffusion Tensor Imaging Parameters and Frailty in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1050-1055.	1.3	19
41	Cognitive, functional, physical, and nutritional status of the oldest old encountered in primary care: a systematic review. <i>BMC Family Practice</i> , 2020, 21, 58.	2.9	12
42	THE FUTURE OF ANTI-AMYLOID TRIALS. <i>Journal of prevention of Alzheimer's disease, The</i> , 2020, 7, 1-6.	1.5	34
43	CORTICAL $\beta$ -AMYLOID IN OLDER ADULTS IS ASSOCIATED WITH MULTIDOMAIN INTERVENTIONS WITH AND WITHOUT OMEGA 3 POLYUNSATURATED FATTY ACID SUPPLEMENTATION. <i>Journal of prevention of Alzheimer's disease, The</i> , 2020, 7, 1-7.	1.5	8
44	Attitudes of at-risk older adults about prevention of cardiovascular disease and dementia using eHealth: a qualitative study in a European context. <i>BMJ Open</i> , 2020, 10, e037050.	0.8	4
45	Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 71-99.	1.1	18
46	ANTI-TAU TRIALS FOR ALZHEIMER'S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019, 6, 1-7.	1.5	48
47	Benzodiazepine use and brain amyloid load in nondemented older individuals: a florbetapir PET study in the Multidomain Alzheimer Preventive Trial cohort. <i>Neurobiology of Aging</i> , 2019, 84, 61-69.	1.5	12
48	Effect of Long-Term Omega 3 Polyunsaturated Fatty Acid Supplementation with or without Multidomain Lifestyle Intervention on Muscle Strength in Older Adults: Secondary Analysis of the Multidomain Alzheimer Preventive Trial (MAPT). <i>Nutrients</i> , 2019, 11, 1931.	1.7	40
49	Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study. <i>Journal of Nutrition, Health and Aging</i> , 2019, 23, 805-812.	1.5	1
50	Absence of Relationship Between Self-Reported Sleep Measures and Amyloid Load in Elderly Subjects. <i>Frontiers in Neurology</i> , 2019, 10, 989.	1.1	18
51	Associations of C-reactive protein and homocysteine concentrations with the impairment of intrinsic capacity domains over a 5-year follow-up among community-dwelling older adults at risk of cognitive decline (MAPT Study). <i>Experimental Gerontology</i> , 2019, 127, 110716.	1.2	39
52	Multidomain intervention and/or omega-3 in nondemented elderly subjects according to amyloid status. <i>Alzheimer's and Dementia</i> , 2019, 15, 1392-1401.	0.4	35
53	PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORT. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019, 6, 1-5.	1.5	43
54	Association of 3-Year Multidomain Intervention and Omega-3 Supplementation with Frailty Incidence. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1700-1706.	1.3	15

#	ARTICLE	IF	CITATIONS
55	COMBINATION THERAPY FOR ALZHEIMER'S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019, 6, 1-5.	1.5	29
56	Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials. <i>Alzheimer's and Dementia</i> , 2019, 15, 729-741.	0.4	68
57	Factors associated with changes of the frailty status after age 70: Findings in the MAPT study. <i>Annals of Epidemiology</i> , 2019, 34, 65-70.e1.	0.9	22
58	Lifestyle multidomain intervention, omega-3 supplementation, or both for reducing the risk of developing clinically relevant depressive symptoms in older adults with memory complaints? Secondary analysis from the MAPT trial. <i>Experimental Gerontology</i> , 2019, 120, 28-34.	1.2	5
59	Defining Vitality: Associations of Three Operational Definitions of Vitality with Disability in Instrumental Activities of Daily Living and Frailty among Elderly Over a 3-Year Follow-Up (MAPT Study). <i>Journal of Nutrition, Health and Aging</i> , 2019, 23, 386-392.	1.5	8
60	A blood-based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 953-963.	1.8	22
61	Estimated Glomerular Filtration Rate Decline and Incident Frailty in Older Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1597-1604.	2.2	14
62	Healthy ageing through internet counselling in the elderly (HATICE): a multinational, randomised controlled trial. <i>The Lancet Digital Health</i> , 2019, 1, e424-e434.	5.9	83
63	Blood pressure and cognitive performances in middle-aged adults. <i>Journal of Hypertension</i> , 2019, 37, 1244-1253.	0.3	15
64	Older Adults' Reasons for Participating in an eHealth Prevention Trial: A Cross-Country, Mixed-Methods Comparison. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 843-849.e5.	1.2	28
65	Ready-meal consumption in older people: association with obesity and dietary intake. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 855-861.	1.4	1
66	Reduced brain amyloid burden in elderly patients with narcolepsy type 1. <i>Annals of Neurology</i> , 2019, 85, 74-83.	2.8	18
67	TRAJECTORY OF THE MAPT-PACC-PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE IN THE PLACEBO GROUP OF A RANDOMIZED CONTROL TRIAL: RESULTS FROM THE MAPT STUDY: LESSONS FOR FURTHER TRIALS. <i>Journal of prevention of Alzheimer's disease, The</i> , 2018, 5, 1-5.	1.5	10
68	Effects of multidomain lifestyle intervention, omega-3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial. <i>Age and Ageing</i> , 2018, 47, 281-288.	0.7	16
69	Prospective associations between white matter hyperintensities and lower extremity function. <i>Neurology</i> , 2018, 90, e1291-e1297.	1.5	27
70	Designing an Internet-Based Multidomain Intervention for the Prevention of Cardiovascular Disease and Cognitive Impairment in Older Adults: The HATICE Trial. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 649-663.	1.2	36
71	Diabetes Care and Dementia Among Older Adults: A Nationwide 3-Year Longitudinal Study. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 601-606.e2.	1.2	9
72	Impact of diabetes on caregiver stress in patients with Alzheimer's disease: data from the ICTUS study. <i>International Psychogeriatrics</i> , 2018, 30, 1109-1117.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Association Between Red Blood Cells Omega-3 Polyunsaturated Fatty Acids and White Matter Hyperintensities: The MAPT Study. <i>Journal of Nutrition, Health and Aging</i> , 2018, 22, 174-179.	1.5	8
74	Red blood cell membrane omega-3 fatty acid levels and physical performance: Cross-sectional data from the MAPT study. <i>Clinical Nutrition</i> , 2018, 37, 1141-1144.	2.3	15
75	Physical activity domains and cognitive function over three years in older adults with subjective memory complaints: Secondary analysis from the MAPT trial. <i>Journal of Science and Medicine in Sport</i> , 2018, 21, 52-57.	0.6	10
76	Physical Activity and Changes in White Matter Hyperintensities over Three Years. <i>Journal of Nutrition, Health and Aging</i> , 2018, 22, 425-430.	1.5	10
77	Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study. <i>Value in Health</i> , 2018, 21, 295-303.	0.1	24
78	WHO GUIDELINES ON COMMUNITY-LEVEL INTERVENTIONS TO MANAGE DECLINES IN INTRINSIC CAPACITY: THE ROAD TO PREVENTION COGNITIVE DECLINE IN OLDER AGE?. <i>Journal of prevention of Alzheimer's disease, The</i> , 2018, 5, 1-3.	1.5	22
79	FATTY ACIDS AND ALZHEIMER'S DISEASE: EVIDENCE ON COGNITION AND CORTICAL $\beta$ -AMYLOID FROM SECONDARY ANALYSES OF THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL. <i>Journal of prevention of Alzheimer's disease, The</i> , 2018, 5, 1-3.	1.5	1
80	WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease, The</i> , 2018, 5, 1-4.	1.5	7
81	A17091 Pulse wave velocity is associated with greater risk of dementia in mild cognitive impairment patients. <i>Journal of Hypertension</i> , 2018, 36, e340.	0.3	1
82	France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 425-427.	1.2	15
83	Pulse Wave Velocity Is Associated With Greater Risk of Dementia in Mild Cognitive Impairment Patients. <i>Hypertension</i> , 2018, 72, 1109-1116.	1.3	37
84	Relationship Between Brain Amyloid Deposition and Instrumental Activities of Daily Living in Older Adults: A Longitudinal Study from the Multidomain Alzheimer Prevention Trial. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1940-1947.	1.3	9
85	Performances of Poisson's Gamma Model for Patients' Recruitment in Clinical Trials When There Are Pauses in Recruitment or When the Number of Centres is Small. <i>Springer Proceedings in Mathematics and Statistics</i> , 2018, , 285-299.	0.1	0
86	Simulated Clinical Trials: Principle, Good Practices, and Focus on Virtual Patients Generation. <i>Springer Proceedings in Mathematics and Statistics</i> , 2018, , 301-314.	0.1	1
87	Effect of Multidomain Intervention, Omega-3 Polyunsaturated Fatty Acids Supplementation or their Combination on Cognitive Function in Non-Demented Older Adults According to Frail Status: Results from the MAPT Study. <i>Journal of Nutrition, Health and Aging</i> , 2018, 22, 923-927.	1.5	19
88	Effects of a 3-Year Multi-Domain Intervention with or without Omega-3 Supplementation on Cognitive Functions in Older Subjects with Increased CAIDE Dementia Scores. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 71-78.	1.2	49
89	Impact of collaborative pharmaceutical care on in-patients' medication safety: study protocol for a stepped wedge cluster randomized trial (MEDREV study). <i>Trials</i> , 2018, 19, 19.	0.7	13
90	Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline?. <i>Journal of Nutrition, Health and Aging</i> , 2018, 22, 982-988.	1.5	13

#	ARTICLE	IF	CITATIONS
91	The "Sarcopenia and Physical Frailty IN older people: multi-component Treatment strategies" (SPRINTT) randomized controlled trial: design and methods. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 89-100.	1.4	131
92	Determinants of Dropout and Nonadherence in a Dementia Prevention Randomized Controlled Trial: The Prevention of Dementia by Intensive Vascular Care Trial. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1505-1513.	1.3	20
93	Reversible states of physical and/or cognitive dysfunction: A 9-year longitudinal study. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 271-275.	1.5	11
94	Effect of dementia on receipt of influenza vaccine: a cohort study in French older adults using administrative data: 2007-2012. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 471-480.	1.0	5
95	On the Fleming-Harrington test for late effects in prevention randomized controlled trials. <i>Journal of Statistical Theory and Practice</i> , 2017, 11, 418-435.	0.3	8
96	Cross-sectional associations of cortical $\beta$ -amyloid with erythrocyte membrane long-chain polyunsaturated fatty acids in older adults with subjective memory complaints. <i>Journal of Neurochemistry</i> , 2017, 142, 589-596.	2.1	10
97	Using Poisson-gamma model to evaluate the duration of recruitment process when historical trials are available. <i>Statistics in Medicine</i> , 2017, 36, 3605-3620.	0.8	9
98	How to deal with the Poisson-gamma model to forecast patients' recruitment in clinical trials when there are pauses in recruitment dynamic?. <i>Contemporary Clinical Trials Communications</i> , 2017, 5, 144-152.	0.5	8
99	Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 377-389.	4.9	576
100	Cognitive Event-Related Potential, an Early Diagnosis Biomarker in Frail Elderly Subjects: The ERP-MAPT-PLUS Ancillary Study. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 87-97.	1.2	4
101	Cognitive changes with omega-3 polyunsaturated fatty acids in non-demented older adults with low omega-3 index. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 988-993.	1.5	45
102	Cross-sectional associations of total plasma homocysteine with cortical $\beta$ -amyloid independently and as a function of omega 3 polyunsaturated fatty acid status in older adults at risk of dementia. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 1075-1080.	1.5	14
103	Association of cortical $\beta$ -amyloid with erythrocyte membrane monounsaturated and saturated fatty acids in older adults at risk of dementia. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 1170-1175.	1.5	4
104	Lessons from the Multidomain Alzheimer Preventive Trial " Authors' reply. <i>Lancet Neurology</i> , The, 2017, 16, 586.	4.9	2
105	Associations between white matter hyperintensities and cognitive decline over three years in non-dementia older adults with memory complaints. <i>Journal of the Neurological Sciences</i> , 2017, 379, 266-270.	0.3	13
106	Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1567-1578.	1.2	15
107	Collaborative efforts to prevent Alzheimer's disease. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 1072-1074.	1.5	1
108	Physical Activity and Incident Chronic Diseases: A Longitudinal Observational Study in 16 European Countries. <i>American Journal of Preventive Medicine</i> , 2017, 52, 373-378.	1.6	58

#	ARTICLE	IF	CITATIONS
109	Development and Validation of an Interactive Internet Platform for Older People: The Healthy Ageing Through Internet Counselling in the Elderly Study. <i>Telemedicine Journal and E-Health</i> , 2017, 23, 96-104.	1.6	36
110	Cross-Sectional and Prospective Associations Between $\beta$ -Amyloid in the Brain and Chair Rise Performance in Nondementia Older Adults With Spontaneous Memory Complaints. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 278-283.	1.7	9
111	Cross-sectional Associations of Fatigue with Cerebral $\beta$ -Amyloid in Older Adults at Risk of Dementia. <i>Frontiers in Medicine</i> , 2017, 4, 173.	1.2	9
112	Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 312.	1.7	26
113	Improving data sharing in research with context-free encoded missing data. <i>PLoS ONE</i> , 2017, 12, e0182362.	1.1	3
114	EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER'S PREVENTION TRIALS. <i>Journal of prevention of Alzheimer's disease, The</i> , 2017, 4, 1-9.	1.5	18
115	Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2017, 14, 255-267.	0.7	2
116	THE ROSAS COHORT: A PROSPECTIVE, LONGITUDINAL STUDY OF BIOMARKERS FOR ALZHEIMER'S DISEASE. STRATEGY, METHODS AND INITIAL RESULTS. <i>Journal of prevention of Alzheimer's disease, The</i> , 2017, 4, 1-11.	1.5	3
117	How Older Persons Perceive the Loss of Independence: The Need of a Holistic Approach to Frailty. <i>Journal of Frailty &amp; Aging, the</i> , 2017, 6, 107-112.	0.8	7
118	kmlShape: An Efficient Method to Cluster Longitudinal Data (Time-Series) According to Their Shapes. <i>PLoS ONE</i> , 2016, 11, e0150738.	1.1	69
119	Frailty Index and Cognitive Decline in Alzheimer's Disease: Data from the Impact of Cholinergic Treatment <sc>US</sc> Study. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1165-1170.	1.3	30
120	Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment. <i>BMJ Open</i> , 2016, 6, e010806.	0.8	75
121	Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. <i>International Psychogeriatrics</i> , 2016, 28, 707-717.	0.6	96
122	Refining Mild-to-Moderate Alzheimer Disease Screening: A Tool for Clinicians. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 913-920.	1.2	3
123	Physical Activity and Cognitive Function in Middle-Aged and Older Adults. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1515-1524.	1.4	45
124	Evaluating the clinical relevance of a cognitive composite outcome measure: An analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial. <i>Alzheimer's and Dementia</i> , 2016, 12, 1216-1225.	0.4	23
125	Caloric restriction and aerobic exercise in sarcopenic and non-sarcopenic obese women: an observational and retrospective study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 284-289.	2.9	22
126	Clinical research for older adults in rural areas: the MINDED study experience. <i>Age</i> , 2016, 38, 30.	3.0	7



#	ARTICLE	IF	CITATIONS
127	Dementia beyond 2025: Knowledge and uncertainties. <i>Dementia</i> , 2016, 15, 6-21.	1.0	48
128	Assessing Alzheimer's disease patients' quality of life: Discrepancies between patient and caregiver perspectives. <i>Alzheimer's and Dementia</i> , 2016, 12, 427-437.	0.4	31
129	Relationship of regional brain $\beta$ -amyloid to gait speed. <i>Neurology</i> , 2016, 86, 36-43.	1.5	119
130	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
131	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , 2016, 15, 455-532.	4.9	1,242
132	Brain Amyloid Deposition Is Associated With Lower Instrumental Activities of Daily Living Abilities in Older Adults. Results From the MAPT Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 391-397.	1.7	19
133	Frailty Index and Incident Mortality, Hospitalization, and Institutionalization in Alzheimer's Disease: Data From the ICTUS Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 543-548.	1.7	34
134	Web-Based Interventions Targeting Cardiovascular Risk Factors in Middle-Aged and Older People: A Systematic Review and Meta-Analysis. <i>Journal of Medical Internet Research</i> , 2016, 18, e55.	2.1	116
135	Physical Activity and Amyloid $\beta$ Brain Levels in Elderly Adults with Intact Cognition and Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1634-1639.	1.3	35
136	Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 793-804.	1.2	28
137	A Longitudinal Study of Transitions Between Informal and Formal Care in Alzheimer Disease Using Multistate Models in the European ICTUS Cohort. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 1104.e1-1104.e7.	1.2	12
138	Analysing time to event data in dementia prevention trials: The example of the guidage study of EGB761A®. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 1009-1011.	1.5	13
139	Dementia Diagnosis and Influenza Vaccination in French Nursing Home Residents. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1256-1258.	1.3	3
140	An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials. <i>Statistics in Medicine</i> , 2015, 34, 541-557.	0.8	16
141	Nutrition and Cognition in Aging Adults. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 453-464.	1.0	22
142	Preventable Iatrogenic Disability in Elderly Patients During Hospitalization. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 674-681.	1.2	111
143	Evolution of General Practitioners' Preferences for Antipsychotics in France, 2003-2010. <i>Psychiatric Services</i> , 2015, 66, 434-437.	1.1	0
144	Antihypertensive Drugs, Prevention of Cognitive Decline and Dementia: A Systematic Review of Observational Studies, Randomized Controlled Trials and Meta-Analyses, with Discussion of Potential Mechanisms. <i>CNS Drugs</i> , 2015, 29, 113-130.	2.7	177

#	ARTICLE	IF	CITATIONS
145	Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. <i>International Psychogeriatrics</i> , 2015, 27, 181-197.	0.6	29
146	Prevention Studies in Alzheimer's Disease: Progress Towards the Development of New Therapeutics. <i>CNS Drugs</i> , 2015, 29, 519-528.	2.7	7
147	Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. <i>Lancet Neurology</i> , The, 2015, 14, 926-944.	4.9	227
148	Living Alone with Alzheimer's Disease and the Risk of Adverse Outcomes: Results from the Plan de Soins et d'Aide dans la maladie d'Alzheimer Study. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 651-658.	1.3	18
149	Understanding the Complexities of Functional Ability in Alzheimer's Disease: More Than Just Basic and Instrumental Factors. <i>Current Alzheimer Research</i> , 2014, 11, 357-366.	0.7	20
150	Normalized Mini-Mental State Examination for Assessing Cognitive Change in Population-Based Brain Aging Studies. <i>Neuroepidemiology</i> , 2014, 43, 15-25.	1.1	58
151	Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 54.	1.7	155
152	P3-341: MANAGEMENT OF VASCULAR AND LIFESTYLE-RELATED RISK FACTORS FOR ALZHEIMER'S DISEASE AND DEMENTIA IN OLDER ADULTS: A EUROPEAN PERSPECTIVE. , 2014, 10, P754-P755.		4
153	Sexually dimorphic patterns of nutritional intake and eating behaviors in community-dwelling older adults with normal and slow gait speed. <i>Journal of Nutrition, Health and Aging</i> , 2014, 18, 228-233.	1.5	22
154	A 2-Year Prospective Cohort Study of Antidementia Drug Non-Persistence in Mild-to-Moderate Alzheimer's Disease in Europe. <i>CNS Drugs</i> , 2014, 28, 157-170.	2.7	20
155	Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings. <i>European Neuropsychopharmacology</i> , 2014, 24, 95-104.	0.3	76
156	Description of 1,108 older patients referred by their physician to the "Geriatric Frailty Clinic (G.F.C) for assessment of frailty and prevention of disability" at the gerontopole. <i>Journal of Nutrition, Health and Aging</i> , 2014, 18, 457-464.	1.5	102
157	The Multidomain Intervention to prevent Disability in Elders (MINDED) project: Rationale and study design of a pilot study. <i>Contemporary Clinical Trials</i> , 2014, 38, 145-154.	0.8	25
158	A comparison of the constant piecewise weighted logrank and Fleming-Harrington tests. <i>Electronic Journal of Statistics</i> , 2014, 8, .	0.4	10
159	A Self-Reported Screening Tool for Detecting Community-Dwelling Older Persons with Frailty Syndrome in the Absence of Mobility Disability: The FiND Questionnaire. <i>PLoS ONE</i> , 2014, 9, e101745.	1.1	77
160	Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making. <i>Journal of prevention of Alzheimer's disease</i> , The, 2014, 1, 117-123.	1.5	9
161	Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs!. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1589-1597.	0.8	68
162	How to design nutritional intervention trials to slow cognitive decline in apparently healthy populations and apply for efficacy claims: A statement from the international academy on nutrition and aging task force. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 619-623.	1.5	11

#	ARTICLE	IF	CITATIONS
163	Promoting access to innovation for frail old persons. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 688-693.	1.5	55
164	Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD expert meeting. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 653-660.	1.5	43
165	Persistent use of Analgesic Medications in Mild-to-Moderate Alzheimer's Disease. <i>Drugs and Aging</i> , 2013, 30, 439-445.	1.3	9
166	Cognitive frailty: Rational and definition from an (I.A.N.A./I.A.G.G.) International Consensus Group. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 726-734.	1.5	659
167	Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia</i> , 2013, 9, S45-55.	0.4	96
168	Early prediction of failure to lose weight after obesity surgery. <i>Surgery for Obesity and Related Diseases</i> , 2013, 9, 118-121.	1.0	30
169	Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study. <i>Journal of Neurology</i> , 2013, 260, 1859-1865.	1.8	35
170	Relationship Between Markers of Insulin Resistance, Markers of Adiposity, HbA1c, and Cognitive Functions in a Middle-Aged Population-Based Sample: the MONA LISA Study. <i>Diabetes Care</i> , 2013, 36, 1512-1521.	4.3	50
171	The cognitive impairment of frail older persons. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 735-737.	1.5	12
172	Comparison of Informal Care Time and Costs in Different Age-Related Dementias: A Review. <i>BioMed Research International</i> , 2013, 2013, 1-15.	0.9	39
173	Weight changes in Alzheimer's disease patients with increased aberrant motor behavior. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 998-1004.	1.3	6
174	Gait Speed, Body Composition, and Dementia. The EPIDOS-Toulouse Cohort. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2012, 67A, 425-432.	1.7	80
175	Falls and Risk Factors for Falls in Community-Dwelling Adults With Dementia (NutriAlz Trial). <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 74-80.	0.6	35
176	Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study. <i>Current Alzheimer Research</i> , 2012, 9, 902-912.	0.7	42
177	Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer's Disease Patients: Evidence for a Role of Dementia Severity. <i>Current Alzheimer Research</i> , 2012, 9, 1106-1116.	0.7	32
178	Psychotropic Drug Consumption at Admission and Discharge of Nursing Home Residents. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 407.e7-407.e12.	1.2	38
179	PND24 Methodological Considerations in Cost of Illness Studies on Alzheimer Disease. <i>Value in Health</i> , 2012, 15, A550.	0.1	0
180	Weight Loss and Rapid Cognitive Decline in Community-Dwelling Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 647-654.	1.2	113

#	ARTICLE	IF	CITATIONS
181	Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. <i>Lancet Neurology</i> , The, 2012, 11, 851-859.	4.9	331
182	Methodological challenges in designing dementia prevention trials – The European Dementia Prevention Initiative (EDPI). <i>Journal of the Neurological Sciences</i> , 2012, 322, 64-70.	0.3	96
183	Exploring the Relationship between Alzheimer's Disease Severity and Longitudinal Costs. <i>Value in Health</i> , 2012, 15, 412-419.	0.1	46
184	Improving Care of Older Adults With Dementia: Description of 6299 Hospitalizations over 11 Years in a Special Acute Care Unit. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 486.e1-486.e6.	1.2	28
185	Methodological considerations in cost of illness studies on Alzheimer disease. <i>Health Economics Review</i> , 2012, 2, 18.	0.8	62
186	Course of neuropsychiatric symptoms during a 4-year follow up in the REAL-FR cohort. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 134-137.	1.5	58
187	Alzheimer's disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 339-345.	1.5	38
188	Representations and practices of prevention in elderly populations: Investigating acceptance to participate in and adhesion to an intervention study for the prevention of Alzheimer's disease (accept) <i>Tj ETQq0 0 Q rgBT /Overlock 10 T</i> 352-354.	1.5	10
189	Recruitment strategies for preventive trials. The MAPT study (Multidomain Alzheimer Preventive Trial). <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 355-359.	1.5	61
190	Diabetes mellitus as a modulator of functional impairment and decline in Alzheimer's disease. The Real.FR cohort. <i>Diabetic Medicine</i> , 2012, 29, 541-548.	1.2	17
191	Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2011, 12, 249-256.	1.2	2,427
192	International Association of Gerontology and Geriatrics: A Global Agenda for Clinical Research and Quality of Care in Nursing Homes. <i>Journal of the American Medical Directors Association</i> , 2011, 12, 184-189.	1.2	215
193	Biomarkers for Alzheimer's disease therapeutic trials. <i>Progress in Neurobiology</i> , 2011, 95, 579-593.	2.8	119
194	Prevention trials in Alzheimer's disease: An EU-US task force report. <i>Progress in Neurobiology</i> , 2011, 95, 594-600.	2.8	62
195	AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia</i> , 2011, 7, e109-17.	0.4	17
196	Suitability of the Clinical Dementia Rating – Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. <i>Alzheimer's and Dementia</i> , 2011, 7, 602.	0.4	79
197	Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. , 2011, 7, 127-132.		35
198	Long-term progression of Alzheimer's disease in patients under antidementia drugs. <i>Alzheimer's and Dementia</i> , 2011, 7, 579-592.	0.4	60

#	ARTICLE	IF	CITATIONS
199	Informal Caregiving and Self-Reported Mental and Physical Health: Results From the Gazel Cohort Study. <i>American Journal of Public Health</i> , 2011, 101, 1971-1979.	1.5	71
200	Public financial support receipt and non-medical resource utilization in Alzheimer's disease results from the PLASA study. <i>Social Science and Medicine</i> , 2011, 72, 1310-1316.	1.8	31
201	Incidence and predictive factors of depressive symptoms in Alzheimer's disease: The REAL.FR study. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 609-617.	1.5	30
202	Health and nutrition promotion program for patients with dementia (NutriAlz): Cluster randomized trial. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 822-830.	1.5	74
203	How Should We Deal with Missing Data in Clinical Trials Involving Alzheimer's Disease Patients?. <i>Current Alzheimer Research</i> , 2011, 8, 421-433.	0.7	26
204	Antidepressant use in Alzheimer's disease patients: results of the REAL.FR cohort. <i>International Psychogeriatrics</i> , 2010, 22, 120-128.	0.6	25
205	Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study). <i>BMJ: British Medical Journal</i> , 2010, 340, c2466-c2466.	2.4	48
206	The primary care physician and Alzheimer's disease: An international position paper. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 110-120.	1.5	83
207	Predictive factors of hospitalizations in Alzheimer's disease: A two-year prospective study in 686 patients of the REAL.FR study. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 288-291.	1.5	38
208	Differences in resource use and costs of dementia care between European countries: Baseline data from the ictus study. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 648-654.	1.5	79
209	Regional Variation on the Presentation of Alzheimer's Disease Patients in Memory Clinics within Europe: Data from the ICTUS Study. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 155-165.	1.2	10
210	Predictive Factors of Discontinuation and Switch of Cholinesterase Inhibitors in Community-Dwelling Patients with Alzheimer's Disease. <i>CNS Drugs</i> , 2010, 24, 431-442.	2.7	29
211	Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 235-270.	1.2	42
212	An Abnormal "One-leg Balance" Test Predicts Cognitive Decline During Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 525-531.	1.2	38
213	Cardiovascular Disease Risk Factors and Progression of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 240-246.	0.7	26
214	Characteristics of Alzheimer's disease patients with a rapid weight loss during a six-year follow-up. <i>Clinical Nutrition</i> , 2009, 28, 141-146.	2.3	45
215	Nutritional assessment of residents in Long-Term Care Facilities (LTCFS): Recommendations of the task force on nutrition and ageing of the IAGG European Region and the IANA. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 475-483.	1.5	90
216	Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people: an International Academy on Nutrition and Aging (IANA) Task Force. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 881-889.	1.5	1,487

#	ARTICLE	IF	CITATIONS
217	Descriptive analysis of hospitalizations of patients with Alzheimer's disease: A two-year prospective study of 686 patients from the REAL.FR study. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 890-892.	1.5	23
218	Biomarkers in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2009, 1180, 119-124.	1.8	26
219	Spared and Impaired Abilities in Community-Dwelling Patients Entering the Severe Stage of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 412-417.	0.7	30
220	Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): A new approach to the prevention of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2009, 5, 114-121.	0.4	90
221	Does Cognitive Impairment Influence Burden in Caregivers of Patients with Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 105-114.	1.2	88
222	Special acute care unit for older adults with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 215-219.	1.3	20
223	A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort). <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 460-465.	1.3	17
224	The prevalence of clinically significant depressive symptoms in Alzheimer's disease: relationship with other psychological and behavioural symptoms. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 1209-1211.	1.3	7
225	Endpoints for trials in Alzheimer's disease: a European task force consensus. <i>Lancet Neurology</i> , The, 2008, 7, 436-450.	4.9	146
226	Prognosis of Alzheimer's disease today: A two-year prospective study in 686 patients from the REAL.FR Study. <i>Alzheimer's and Dementia</i> , 2008, 4, 22-29.	0.4	84
227	Memory health clinics "a first step to prevention. <i>Alzheimer's and Dementia</i> , 2008, 4, S144-9.	0.4	5
228	Dementia Prevention: Methodological Explanations for Inconsistent Results. <i>Epidemiologic Reviews</i> , 2008, 30, 35-66.	1.3	145
229	Predictive Factors of Attrition in a Cohort of Alzheimer Disease Patients. <i>Neuroepidemiology</i> , 2008, 31, 69-79.	1.1	47
230	GuidAge Study: A 5-Year Double Blind, Randomised Trial of EGb 761 for the Prevention of Alzheimer's Disease in Elderly Subjects with Memory Complaints. I. Rationale, Design and Baseline Data. <i>Current Alzheimer Research</i> , 2008, 5, 406-415.	0.7	47
231	Disease Modifying Trials in Alzheimer's Disease: Perspectives for the Future. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 289-301.	1.2	15
232	Predictive Value of Rapid Decline in Mini Mental State Examination in Clinical Practice for Prognosis in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 109-116.	0.7	44
233	The ICTUS Study: A Prospective Longitudinal Observational Study of 1,380 AD Patients in Europe. <i>Neuroepidemiology</i> , 2007, 29, 29-38.	1.1	51
234	RESPONSE TO LETTER FROM GARCIA AND COLLEAGUES ON CHOLINESTERASE INHIBITORS AND ALZHEIMER'S DISEASE OUTCOMES. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2007, 62, 679-680.	1.7	1

#	ARTICLE	IF	CITATIONS
235	Predictive Value of 6-Month Decline in ADAS-cog for Survival without Severe Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 168-174.	0.7	14
236	Wandering Behavior and Alzheimer Disease. The REAL.FR Prospective Study. <i>Alzheimer Disease and Associated Disorders</i> , 2007, 21, 31-38.	0.6	50
237	New assessment of dependency in demented patients: Impact on the quality of life in informal caregivers. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 234-242.	1.0	27
238	Exercise Program for Nursing Home Residents with Alzheimer's Disease: A 1-Year Randomized, Controlled Trial. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 158-165.	1.3	554
239	Disease-modifying trials in Alzheimer's disease: a European task force consensus. <i>Lancet Neurology</i> , 2007, 6, 56-62.	4.9	142
240	Outcome of Alzheimer's Disease: Potential Impact of Cholinesterase Inhibitors. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 516-520.	1.7	35
241	Different modes of weight loss in Alzheimer disease: a prospective study of 395 patients. <i>American Journal of Clinical Nutrition</i> , 2005, 82, 435-441.	2.2	96
242	Cognitive impairment and composition of drinking water in women: findings of the EPIDOS Study. <i>American Journal of Clinical Nutrition</i> , 2005, 81, 897-902.	2.2	59
243	Beyond the global score of the Zarit Burden Interview: useful dimensions for clinicians. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 254-260.	1.3	161
244	Different modes of weight loss in Alzheimer disease: a prospective study of 395 patients. <i>American Journal of Clinical Nutrition</i> , 2005, 82, 435-441.	2.2	96
245	Minimum Data Set for Nutritional Intervention Studies in Elderly People. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2004, 59, M724-M729.	1.7	14
246	Improvement of Weight and Fat-Free Mass with Oral Nutritional Supplementation in Patients with Alzheimer's Disease at Risk of Malnutrition: A Prospective Randomized Study. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1702-1707.	1.3	146
247	Body composition in French women 75+ years of age: The EPIDOS study. <i>Mechanisms of Ageing and Development</i> , 2003, 124, 311-316.	2.2	64
248	Comparison of bone mineral density and body composition measurements in women obtained from two DXA instruments. <i>Mechanisms of Ageing and Development</i> , 2003, 124, 317-321.	2.2	30
249	Association of Alzheimer's Disease Onset With Ginkgo Biloba and Other Symptomatic Cognitive Treatments in a Population of Women Aged 75 Years and Older From the EPIDOS Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2003, 58, M372-M377.	1.7	73
250	Music Perception in Adult Cochlear Implant Recipients. <i>Acta Oto-Laryngologica</i> , 2003, 123, 826-835.	0.3	155
251	Predictive factors of acute hospitalization in 134 patients with Alzheimer's disease: a one year prospective study. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 422-426.	1.3	55
252	Cognitive function and caregiver burden: predictive factors for eating behaviour disorders in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 950-955.	1.3	67

#	ARTICLE	IF	CITATIONS
253	Is There a Relationship Between Fat-Free Soft Tissue Mass and Low Cognitive Function? Results From a Study of 7,105 Women. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 1796-1801.	1.3	128
254	Nutrition assessment in the elderly. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2001, 4, 5-8.	1.3	90
255	Instrumental Activities of Daily Living as a Potential Marker of Frailty: A Study of 7364 Community-Dwelling Elderly Women (the EPIDOS Study). <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2001, 56, M448-M453.	1.7	176
256	Weight loss in Alzheimer disease. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 637S-642S.	2.2	205
257	Alzheimer disease: protective factors. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 643S-649S.	2.2	94